How possible is the development of an operational psychometric method to assess the presence of the 5-HTTLPR s allele? Equivocal preliminary findings.
OBJECTIVE
The s allele of the 5-hydroxytryptamine transporter-linked promoter region (5-HTTLPR) polymorphism of the serotonin transporter gene has been found to be associated with neuroticism-related traits, affective temperaments and response to selective serotonin reuptake inhibitor (SSRI) treatment. The aim of the current study was to develop a psychometric tool that could at least partially substitute for laboratory testing and could predict the presence of the s allele.


METHODS
The study included 138 women of Caucasian origin, mean 32.20 +/- 1.02 years old. All subjects completed the Hungarian standardised version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A) instrument and were genotyped for 5-HTTLPR using PCR. The statistical analysis included the calculation of the Index of Discrimination (D), Discriminant Function Analysis, creation of scales on the basis of the above and then item analysis and calculation of sensitivity and specificity.


RESULTS
Four indices were eventually developed, but their psychometric properties were relatively poor and their joint application did not improve the outcome.


CONCLUSIONS
We could not create a scale that predicts the 5-HTTLPR genotype with sufficient sensitivity and specificity, therefore we could not substitute a psychometric scale for laboratory genetic testing in predicting genotype, and also possibly affective disorder characterisation and treatment.
Gonda
Xenia
X
Department of Pharmacodynamics, Semmelweis University, Faculty of Medicine, Budapest, Hungary. kendermagos@yahoo.com
Fountoulakis
Konstantinos N
KN
Rihmer
Zoltan
Z
Laszik
Andras
A
Akiskal
Hagop S
HS
Bagdy
Gyorgy
G
J Affect Disord. 2005 Aug;87(2-3):291-7
16002148
Neuropsychopharmacology. 2000 Nov;23(5):587-90
11027924
Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127B(1):85-9
15108187
Mol Psychiatry. 1996 Dec;1(6):453-60
9154246
Mol Psychiatry. 1998 Nov;3(6):508-11
9857976
Biol Psychiatry. 1999 Feb 1;45(3):368-70
10023516
Am J Med Genet. 2001 Jul 8;105(5):458-63
11449399
J Neurochem. 1996 Jun;66(6):2621-4
8632190
J Affect Disord. 2008 Feb;106(1-2):45-53
17706791
J Affect Disord. 2003 Jan;73(1-2):99-104
12507742
Arch Gen Psychiatry. 2004 Nov;61(11):1163-9
15520364
Neurosci Lett. 1998 Oct 23;255(3):143-6
9832193
J Affect Disord. 2005 Mar;85(1-2):1-2
15780670
Psychiatr Genet. 2008 Aug;18(4):184-90
18628680
Arch Gen Psychiatry. 1998 Oct;55(10):936-40
9783565
Can J Psychiatry. 2001 Feb;46(1):35-44
11221488
Biotechniques. 1991 Apr;10(4):506-13
1867860
Science. 1996 Nov 29;274(5292):1527-31
8929413
J Clin Psychopharmacol. 2000 Feb;20(1):105-7
10653220
Neurosci Lett. 2002 Dec 6;334(1):17-20
12431765
Psychiatr Genet. 2004 Sep;14(3):121-9
15318024
Arch Gen Psychiatry. 2006 Oct;63(10):1113-20
17015813
J Affect Disord. 2005 Mar;85(1-2):127-33
15780683
J Affect Disord. 2009 Jan;112(1-3):19-29
18455241
J Affect Disord. 2006 Apr;91(2-3):125-31
16464506
Biol Psychiatry. 2006 Jul 15;60(2):84-92
16300747
Psychiatr Hung. 2006;21(2):147-60
16929079
Mol Psychiatry. 2007 Mar;12(3):247-57
17146470
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1062-73
15951088